Alnylam Pharmaceuticals – Positive Clinical Data Hurting Stock Performance

ALNY – Alnylam Pharmaceuticals – dropped 10% today (Monday, December 7, 2015). It closed at $97.72. On Friday, December 4th, 2015, ALNY closed at $109.

On Sunday, ALNY announced positive Phase 1/2 trial of one of its drugs.

The sell-off could be attributed to overall sell-off in biotech sector.

If ALNY does not stop at $97 level then we could possibly see $88 before it finds its next support.

Chart of ALNY is shown below.

alnylam pharmaceuticals alnylam pharmaceuticals Alnylam Pharmaceuticals - Positive Clinical Data Hurting Stock Performance ALNY Chart Dec7 2015

 

 

 

 

 

 

Related Posts

ALNY Pharma Selling Off Today – But Why?

These 3 Biotechs Are Winning in the Clinic

BlueBird Bio Craters Ater Gene Therapy Disappoints

To find out about companies like ALNY (Alnylam Pharmaceuticals) that are releasing positive trial data but still selling-off, it is important to be a subscriber of options trading services provided by Financial Markets Wizard.

Leave a Reply

Your email address will not be published.